EUVIMEDEUVIMED entdecken
Crossref

In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales

Marion Dutkiewicz, Agnès B Jousset, Hippolyte de Swardt, Inès Rezzoug, Rémy A Bonnin, Laurent Dortet iD, Cécile Emeraud

Journal of Antimicrobial Chemotherapy · 06.01.2026 · 81 (1)

DOI: 10.1093/jac/dkaf440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.12.2025. Verfasst von Marion Dutkiewicz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Team 'Resist' UMR1184 'Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB),' INSERM, Université Paris-Saclay, CEA, LabEx…. Hauptthemen laut MEDLINE: Cefepime, Cephalosporins, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: French National Reference Center for Antimicrobial Resistance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Carbapenemase-producing Enterobacterales (CPE) are a public health concern. Developing novel antibiotics, particularly combinations of β-lactam/β-lactamase inhibitors active against carbapenemases, is critical. Three recent combinations, cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam, are among the most promising. To assess the in vitro activity of these three combinations against a collection of recent CPE clinical isolates and to analyse resistance patterns.

Methods

MICs were determined for 1600 CPE isolates collected over 6-month period in 2024 at the French National Reference Centre for Antimicrobial Resistance. All isolates were fully characterized by whole-genome sequencing.

Results

Among KPC producers, cefepime-enmetazobactam susceptibility was 54%, with higher MICs in Klebsiella pneumoniae ST-307, ST-101 and ST-258. It was active against 90% of OXA-48-like producers and resistance was primarily observed in Citrobacter freundii ST-22 and K. pneumoniae ST-2096. Cefepime-taniborbactam showed excellent activity against KPC- (100%), OXA-48-like (95%), and VIM producers (98%), but lower efficacy (76%) against NDM producers. Resistance was mainly found in NDM-5 producers, especially E. coli ST-140, ST-167, and K. pneumoniae ST-147. All resistant E. coli displayed a 4-amino-acid insertion in PBP3. Cefepime-zidebactam exhibited strong activity towards all CPE types; regarding MBLs, its low MIC values were comparable to aztreonam-avibactam and lower than cefiderocol. Resistant isolates were mostly clonal NDM-14-producing K. pneumoniae ST-147. No cross-resistance, including with aztreonam-avibactam, was observed.

Conclusions

This study support the use of cefepime-enmetazobactam against ESBL/OXA-48-like co-producers. Cefepime-taniborbactam may be use against KPC and VIM producers and could represent a second-line option for NDM. Cefepime-zidebactam shows the most promising activity against MBLs, although already emerging resistance calls for caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefepimeCephalosporinsAnti-Bacterial Agentsbeta-LactamasesBacterial ProteinsCyclooctanesbeta-Lactamase InhibitorsEnterobacteriaceaeBorinic AcidsCarbapenem-Resistant EnterobacteriaceaeMicrobial Sensitivity TestsHumansEnterobacteriaceae InfectionsWhole Genome SequencingAzabicyclo CompoundsDrug CombinationsKlebsiella pneumoniaeHeterocyclic Compounds, 1-RingCarboxylic AcidsPiperidinesTriazoles

Substanzen

CefepimeCephalosporinsAnti-Bacterial Agentsbeta-LactamasescarbapenemaseBacterial ProteinsCyclooctanescefepime-zidebactamtaniborbactamenmetazobactam

Autor:innen und Institutionen

  • Team 'Resist' UMR1184 'Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB),' INSERM, Université Paris-Saclay, CEA, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
  • Bacteriology-Hygiene Unit, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, 78 rue du Général Leclerc, Le Kremlin-Bicêtre, France.
  • Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacteriaceae, Le Kremlin-Bicêtre, France.

ORCID-Profile: Laurent Dortet

Förderung

  • French National Reference Center for Antimicrobial Resistance

Zitieren

APA

Dutkiewicz, M., Jousset, A. B., de Swardt, H., Rezzoug, I., Bonnin, R. A., Dortet, L., & Emeraud, C. (2026). In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales. Journal of Antimicrobial Chemotherapy, 81(1). https://doi.org/10.1093/jac/dkaf440

Vancouver

Dutkiewicz M, Jousset AB, de Swardt H, Rezzoug I, Bonnin RA, Dortet L, et al. In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales. Journal of Antimicrobial Chemotherapy. 2026;81(1). doi:10.1093/jac/dkaf440

BibTeX
@article{Dutkiewicz2026,
  author = {Dutkiewicz, Marion and Jousset, Agnès B and de Swardt, Hippolyte and Rezzoug, Inès and Bonnin, Rémy A and Dortet, Laurent and Emeraud, Cécile},
  title = {In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {1},
  doi = {10.1093/jac/dkaf440}
}
Kostenlos starten →